[Combined administration of futraful and esquinone for the treatment of advanced ovarian cancer].
Thirty-seven patients with advanced ovarian cancer were treated with futraful (FT-207) and esquinone (CQ). These patients had infiltrated tumors to the pelvic and peritoneal cavity and also distant metastasis, so they were not operated perfectly. There were evaluable 12 patients out of 37. FT-207 + CQ is an effective drug combination against advanced ovarian cancer with an overall response rete of 40.9%, a complete response rate of 4.5% (1/22), partial response rate of 36.4% (8/22), no change rate of 27.3% (6/22) and progressive rate of 31.8% (7/22). Patients with adenocarcinoma showed a response rate of 66.7% (8/12). According to the stage, the patients in stage III showed response rate of 50.0% (6/12), in stage IV showed a response rate of 37.5% (3/8). The total dose of FT-207 used in the study was 38.3g in the progressive disease group and 177.6 in the good response group. The group of long term administration of FT-207 and CQ included many patients with good response.
D000230:Adenocarcinoma / Q000188:drug therapy; D001389:Azirines / Q000008:administration & dosage*; D002225:Carbazilquinone / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects
D001389:Azirines; D005641:Tegafur; D002225:Carbazilquinone; D005472:Fluorouracil